nodes	percent_of_prediction	percent_of_DWPC	metapath
Tiagabine—SLC6A1—prostate gland—urinary bladder cancer	0.032	0.271	CbGeAlD
Tiagabine—CYP3A4—Thiotepa—urinary bladder cancer	0.0308	0.687	CbGbCtD
Tiagabine—SLC6A1—seminal vesicle—urinary bladder cancer	0.027	0.229	CbGeAlD
Tiagabine—SLC6A1—Amine compound SLC transporters—SLC14A2—urinary bladder cancer	0.0226	0.274	CbGpPWpGaD
Tiagabine—SLC6A1—urethra—urinary bladder cancer	0.0214	0.182	CbGeAlD
Tiagabine—SLC6A1—female reproductive system—urinary bladder cancer	0.0174	0.148	CbGeAlD
Tiagabine—CYP3A4—urine—urinary bladder cancer	0.0139	0.118	CbGeAlD
Tiagabine—SLC6A1—Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds—SLC14A2—urinary bladder cancer	0.00883	0.107	CbGpPWpGaD
Tiagabine—CYP3A4—Etoposide—urinary bladder cancer	0.00836	0.186	CbGbCtD
Tiagabine—SLC6A1—NRF2 pathway—UGT2B7—urinary bladder cancer	0.00582	0.0706	CbGpPWpGaD
Tiagabine—CYP3A4—Doxorubicin—urinary bladder cancer	0.0057	0.127	CbGbCtD
Tiagabine—CYP3A4—Codeine and Morphine Metabolism—UGT2B7—urinary bladder cancer	0.00497	0.0603	CbGpPWpGaD
Tiagabine—SLC6A1—SLC-mediated transmembrane transport—SLC14A2—urinary bladder cancer	0.00401	0.0487	CbGpPWpGaD
Tiagabine—CYP3A4—renal system—urinary bladder cancer	0.00341	0.0289	CbGeAlD
Tiagabine—CYP3A4—female reproductive system—urinary bladder cancer	0.00273	0.0232	CbGeAlD
Tiagabine—CYP3A4—Estrogen metabolism—UGT2B7—urinary bladder cancer	0.0026	0.0315	CbGpPWpGaD
Tiagabine—CYP3A4—Tamoxifen metabolism—UGT2B7—urinary bladder cancer	0.0023	0.0279	CbGpPWpGaD
Tiagabine—SLC6A1—NRF2 pathway—NQO1—urinary bladder cancer	0.00225	0.0273	CbGpPWpGaD
Tiagabine—SLC6A1—Monoamine Transport—TNF—urinary bladder cancer	0.00221	0.0268	CbGpPWpGaD
Tiagabine—SLC6A1—Transmembrane transport of small molecules—SLC14A2—urinary bladder cancer	0.00204	0.0247	CbGpPWpGaD
Tiagabine—SLC6A1—NRF2 pathway—GSTP1—urinary bladder cancer	0.00187	0.0227	CbGpPWpGaD
Tiagabine—CYP3A4—Oxidation by Cytochrome P450—POR—urinary bladder cancer	0.00186	0.0226	CbGpPWpGaD
Tiagabine—SLC6A1—NRF2 pathway—GSTM1—urinary bladder cancer	0.00172	0.0209	CbGpPWpGaD
Tiagabine—CYP3A4—Aflatoxin B1 metabolism—GSTM1—urinary bladder cancer	0.00164	0.0198	CbGpPWpGaD
Tiagabine—SLC6A1—Transmembrane transport of small molecules—AQP3—urinary bladder cancer	0.00147	0.0179	CbGpPWpGaD
Tiagabine—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—CYP4B1—urinary bladder cancer	0.00141	0.0171	CbGpPWpGaD
Tiagabine—SLC6A1—Transmembrane transport of small molecules—TRPV1—urinary bladder cancer	0.0012	0.0146	CbGpPWpGaD
Tiagabine—CYP3A4—Estrogen metabolism—NQO1—urinary bladder cancer	0.001	0.0122	CbGpPWpGaD
Tiagabine—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP4B1—urinary bladder cancer	0.000893	0.0108	CbGpPWpGaD
Tiagabine—CYP3A4—Oxidation by Cytochrome P450—CYP4B1—urinary bladder cancer	0.000881	0.0107	CbGpPWpGaD
Tiagabine—SLC6A1—Transmembrane transport of small molecules—TFRC—urinary bladder cancer	0.000811	0.00984	CbGpPWpGaD
Tiagabine—CYP3A4—Estrogen metabolism—GSTM1—urinary bladder cancer	0.000769	0.00932	CbGpPWpGaD
Tiagabine—CYP3A4—Phase 1 - Functionalization of compounds—CYP4B1—urinary bladder cancer	0.000724	0.00878	CbGpPWpGaD
Tiagabine—CYP3A4—Constitutive Androstane Receptor Pathway—SMC1A—urinary bladder cancer	0.000721	0.00874	CbGpPWpGaD
Tiagabine—CYP3A4—Biological oxidations—GSTZ1—urinary bladder cancer	0.000492	0.00597	CbGpPWpGaD
Tiagabine—CYP3A4—Metapathway biotransformation—GSTZ1—urinary bladder cancer	0.000486	0.00589	CbGpPWpGaD
Tiagabine—CYP3A4—Biological oxidations—GSTO2—urinary bladder cancer	0.000467	0.00566	CbGpPWpGaD
Tiagabine—CYP3A4—Biological oxidations—NAT1—urinary bladder cancer	0.000467	0.00566	CbGpPWpGaD
Tiagabine—CYP3A4—Metapathway biotransformation—GSTO2—urinary bladder cancer	0.00046	0.00559	CbGpPWpGaD
Tiagabine—SLC6A1—Transmission across Chemical Synapses—HRAS—urinary bladder cancer	0.00043	0.00521	CbGpPWpGaD
Tiagabine—CYP3A4—Biological oxidations—UGT2B7—urinary bladder cancer	0.000427	0.00518	CbGpPWpGaD
Tiagabine—CYP3A4—Metapathway biotransformation—UGT2B7—urinary bladder cancer	0.000421	0.00511	CbGpPWpGaD
Tiagabine—Fatigue—Etoposide—urinary bladder cancer	0.000394	0.000523	CcSEcCtD
Tiagabine—Neuropathy peripheral—Epirubicin—urinary bladder cancer	0.000394	0.000522	CcSEcCtD
Tiagabine—Stomatitis—Epirubicin—urinary bladder cancer	0.000392	0.000519	CcSEcCtD
Tiagabine—Constipation—Etoposide—urinary bladder cancer	0.000391	0.000518	CcSEcCtD
Tiagabine—Pain—Etoposide—urinary bladder cancer	0.000391	0.000518	CcSEcCtD
Tiagabine—Conjunctivitis—Epirubicin—urinary bladder cancer	0.000391	0.000518	CcSEcCtD
Tiagabine—Urinary tract infection—Epirubicin—urinary bladder cancer	0.000391	0.000518	CcSEcCtD
Tiagabine—Dysuria—Doxorubicin—urinary bladder cancer	0.00039	0.000517	CcSEcCtD
Tiagabine—Hypersensitivity—Fluorouracil—urinary bladder cancer	0.000388	0.000514	CcSEcCtD
Tiagabine—Haemoglobin—Methotrexate—urinary bladder cancer	0.000388	0.000514	CcSEcCtD
Tiagabine—Haemorrhage—Methotrexate—urinary bladder cancer	0.000386	0.000511	CcSEcCtD
Tiagabine—Sweating—Epirubicin—urinary bladder cancer	0.000385	0.000511	CcSEcCtD
Tiagabine—Pollakiuria—Doxorubicin—urinary bladder cancer	0.000385	0.000511	CcSEcCtD
Tiagabine—CYP3A4—Biological oxidations—CYP4B1—urinary bladder cancer	0.000384	0.00466	CbGpPWpGaD
Tiagabine—Asthenia—Gemcitabine—urinary bladder cancer	0.000384	0.000509	CcSEcCtD
Tiagabine—Haematuria—Epirubicin—urinary bladder cancer	0.000383	0.000508	CcSEcCtD
Tiagabine—Pharyngitis—Methotrexate—urinary bladder cancer	0.000383	0.000507	CcSEcCtD
Tiagabine—Photosensitivity reaction—Doxorubicin—urinary bladder cancer	0.000381	0.000505	CcSEcCtD
Tiagabine—SLC6A1—Transmembrane transport of small molecules—CREBBP—urinary bladder cancer	0.00038	0.00461	CbGpPWpGaD
Tiagabine—Weight increased—Doxorubicin—urinary bladder cancer	0.00038	0.000503	CcSEcCtD
Tiagabine—Epistaxis—Epirubicin—urinary bladder cancer	0.000379	0.000502	CcSEcCtD
Tiagabine—CYP3A4—Metapathway biotransformation—CYP4B1—urinary bladder cancer	0.000379	0.0046	CbGpPWpGaD
Tiagabine—Pruritus—Gemcitabine—urinary bladder cancer	0.000379	0.000502	CcSEcCtD
Tiagabine—Nausea—Thiotepa—urinary bladder cancer	0.000378	0.000501	CcSEcCtD
Tiagabine—Weight decreased—Doxorubicin—urinary bladder cancer	0.000377	0.0005	CcSEcCtD
Tiagabine—Sinusitis—Epirubicin—urinary bladder cancer	0.000377	0.0005	CcSEcCtD
Tiagabine—Feeling abnormal—Etoposide—urinary bladder cancer	0.000377	0.000499	CcSEcCtD
Tiagabine—Hyperglycaemia—Doxorubicin—urinary bladder cancer	0.000376	0.000499	CcSEcCtD
Tiagabine—Pneumonia—Doxorubicin—urinary bladder cancer	0.000374	0.000496	CcSEcCtD
Tiagabine—Gastrointestinal pain—Etoposide—urinary bladder cancer	0.000374	0.000496	CcSEcCtD
Tiagabine—Pruritus—Fluorouracil—urinary bladder cancer	0.000373	0.000494	CcSEcCtD
Tiagabine—Visual impairment—Methotrexate—urinary bladder cancer	0.000372	0.000492	CcSEcCtD
Tiagabine—Hypersensitivity—Cisplatin—urinary bladder cancer	0.000368	0.000487	CcSEcCtD
Tiagabine—Diarrhoea—Gemcitabine—urinary bladder cancer	0.000367	0.000486	CcSEcCtD
Tiagabine—Renal failure—Doxorubicin—urinary bladder cancer	0.000366	0.000484	CcSEcCtD
Tiagabine—Neuropathy peripheral—Doxorubicin—urinary bladder cancer	0.000365	0.000483	CcSEcCtD
Tiagabine—Urticaria—Etoposide—urinary bladder cancer	0.000363	0.000481	CcSEcCtD
Tiagabine—Haemoglobin—Epirubicin—urinary bladder cancer	0.000363	0.000481	CcSEcCtD
Tiagabine—Stomatitis—Doxorubicin—urinary bladder cancer	0.000363	0.00048	CcSEcCtD
Tiagabine—Rhinitis—Epirubicin—urinary bladder cancer	0.000362	0.000479	CcSEcCtD
Tiagabine—Body temperature increased—Etoposide—urinary bladder cancer	0.000362	0.000479	CcSEcCtD
Tiagabine—Abdominal pain—Etoposide—urinary bladder cancer	0.000362	0.000479	CcSEcCtD
Tiagabine—Urinary tract infection—Doxorubicin—urinary bladder cancer	0.000362	0.000479	CcSEcCtD
Tiagabine—Conjunctivitis—Doxorubicin—urinary bladder cancer	0.000362	0.000479	CcSEcCtD
Tiagabine—Haemorrhage—Epirubicin—urinary bladder cancer	0.000361	0.000478	CcSEcCtD
Tiagabine—Diarrhoea—Fluorouracil—urinary bladder cancer	0.00036	0.000477	CcSEcCtD
Tiagabine—Tinnitus—Methotrexate—urinary bladder cancer	0.00036	0.000476	CcSEcCtD
Tiagabine—Hypoaesthesia—Epirubicin—urinary bladder cancer	0.000359	0.000476	CcSEcCtD
Tiagabine—Asthenia—Cisplatin—urinary bladder cancer	0.000358	0.000475	CcSEcCtD
Tiagabine—Pharyngitis—Epirubicin—urinary bladder cancer	0.000358	0.000475	CcSEcCtD
Tiagabine—Sweating—Doxorubicin—urinary bladder cancer	0.000357	0.000472	CcSEcCtD
Tiagabine—Oedema peripheral—Epirubicin—urinary bladder cancer	0.000356	0.000471	CcSEcCtD
Tiagabine—Haematuria—Doxorubicin—urinary bladder cancer	0.000355	0.00047	CcSEcCtD
Tiagabine—Epistaxis—Doxorubicin—urinary bladder cancer	0.000351	0.000465	CcSEcCtD
Tiagabine—Sinusitis—Doxorubicin—urinary bladder cancer	0.000349	0.000462	CcSEcCtD
Tiagabine—Dizziness—Fluorouracil—urinary bladder cancer	0.000348	0.000461	CcSEcCtD
Tiagabine—Visual impairment—Epirubicin—urinary bladder cancer	0.000348	0.000461	CcSEcCtD
Tiagabine—Chills—Methotrexate—urinary bladder cancer	0.000346	0.000458	CcSEcCtD
Tiagabine—Diarrhoea—Cisplatin—urinary bladder cancer	0.000342	0.000453	CcSEcCtD
Tiagabine—Alopecia—Methotrexate—urinary bladder cancer	0.000341	0.000452	CcSEcCtD
Tiagabine—Vomiting—Gemcitabine—urinary bladder cancer	0.000341	0.000451	CcSEcCtD
Tiagabine—Rash—Gemcitabine—urinary bladder cancer	0.000338	0.000448	CcSEcCtD
Tiagabine—Dermatitis—Gemcitabine—urinary bladder cancer	0.000337	0.000447	CcSEcCtD
Tiagabine—Hypersensitivity—Etoposide—urinary bladder cancer	0.000337	0.000447	CcSEcCtD
Tiagabine—Tinnitus—Epirubicin—urinary bladder cancer	0.000337	0.000446	CcSEcCtD
Tiagabine—Haemoglobin—Doxorubicin—urinary bladder cancer	0.000336	0.000445	CcSEcCtD
Tiagabine—Headache—Gemcitabine—urinary bladder cancer	0.000336	0.000445	CcSEcCtD
Tiagabine—Vomiting—Fluorouracil—urinary bladder cancer	0.000335	0.000444	CcSEcCtD
Tiagabine—Rhinitis—Doxorubicin—urinary bladder cancer	0.000335	0.000444	CcSEcCtD
Tiagabine—Haemorrhage—Doxorubicin—urinary bladder cancer	0.000334	0.000442	CcSEcCtD
Tiagabine—Hypoaesthesia—Doxorubicin—urinary bladder cancer	0.000332	0.00044	CcSEcCtD
Tiagabine—Rash—Fluorouracil—urinary bladder cancer	0.000332	0.00044	CcSEcCtD
Tiagabine—Dermatitis—Fluorouracil—urinary bladder cancer	0.000332	0.00044	CcSEcCtD
Tiagabine—Pharyngitis—Doxorubicin—urinary bladder cancer	0.000331	0.000439	CcSEcCtD
Tiagabine—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—urinary bladder cancer	0.000331	0.00402	CbGpPWpGaD
Tiagabine—Headache—Fluorouracil—urinary bladder cancer	0.00033	0.000437	CcSEcCtD
Tiagabine—SLC6A1—Neuronal System—HRAS—urinary bladder cancer	0.000329	0.00399	CbGpPWpGaD
Tiagabine—Oedema peripheral—Doxorubicin—urinary bladder cancer	0.000329	0.000436	CcSEcCtD
Tiagabine—Dysgeusia—Methotrexate—urinary bladder cancer	0.000329	0.000436	CcSEcCtD
Tiagabine—Asthenia—Etoposide—urinary bladder cancer	0.000328	0.000435	CcSEcCtD
Tiagabine—Back pain—Methotrexate—urinary bladder cancer	0.000325	0.00043	CcSEcCtD
Tiagabine—Chills—Epirubicin—urinary bladder cancer	0.000324	0.000429	CcSEcCtD
Tiagabine—Pruritus—Etoposide—urinary bladder cancer	0.000324	0.000429	CcSEcCtD
Tiagabine—Visual impairment—Doxorubicin—urinary bladder cancer	0.000322	0.000426	CcSEcCtD
Tiagabine—Alopecia—Epirubicin—urinary bladder cancer	0.000319	0.000423	CcSEcCtD
Tiagabine—Nausea—Gemcitabine—urinary bladder cancer	0.000318	0.000422	CcSEcCtD
Tiagabine—Vomiting—Cisplatin—urinary bladder cancer	0.000317	0.000421	CcSEcCtD
Tiagabine—Rash—Cisplatin—urinary bladder cancer	0.000315	0.000417	CcSEcCtD
Tiagabine—Dermatitis—Cisplatin—urinary bladder cancer	0.000315	0.000417	CcSEcCtD
Tiagabine—Diarrhoea—Etoposide—urinary bladder cancer	0.000313	0.000415	CcSEcCtD
Tiagabine—Nausea—Fluorouracil—urinary bladder cancer	0.000313	0.000415	CcSEcCtD
Tiagabine—Ill-defined disorder—Methotrexate—urinary bladder cancer	0.000312	0.000413	CcSEcCtD
Tiagabine—Tinnitus—Doxorubicin—urinary bladder cancer	0.000311	0.000413	CcSEcCtD
Tiagabine—Anaemia—Methotrexate—urinary bladder cancer	0.00031	0.000411	CcSEcCtD
Tiagabine—Flatulence—Epirubicin—urinary bladder cancer	0.00031	0.00041	CcSEcCtD
Tiagabine—Tension—Epirubicin—urinary bladder cancer	0.000308	0.000408	CcSEcCtD
Tiagabine—Dysgeusia—Epirubicin—urinary bladder cancer	0.000308	0.000408	CcSEcCtD
Tiagabine—Nervousness—Epirubicin—urinary bladder cancer	0.000305	0.000404	CcSEcCtD
Tiagabine—Back pain—Epirubicin—urinary bladder cancer	0.000304	0.000403	CcSEcCtD
Tiagabine—Malaise—Methotrexate—urinary bladder cancer	0.000303	0.000401	CcSEcCtD
Tiagabine—Dizziness—Etoposide—urinary bladder cancer	0.000302	0.000401	CcSEcCtD
Tiagabine—Muscle spasms—Epirubicin—urinary bladder cancer	0.000302	0.0004	CcSEcCtD
Tiagabine—Vertigo—Methotrexate—urinary bladder cancer	0.000302	0.0004	CcSEcCtD
Tiagabine—Leukopenia—Methotrexate—urinary bladder cancer	0.000301	0.000398	CcSEcCtD
Tiagabine—Chills—Doxorubicin—urinary bladder cancer	0.0003	0.000397	CcSEcCtD
Tiagabine—Nausea—Cisplatin—urinary bladder cancer	0.000297	0.000393	CcSEcCtD
Tiagabine—Alopecia—Doxorubicin—urinary bladder cancer	0.000295	0.000391	CcSEcCtD
Tiagabine—Cough—Methotrexate—urinary bladder cancer	0.000293	0.000388	CcSEcCtD
Tiagabine—Ill-defined disorder—Epirubicin—urinary bladder cancer	0.000292	0.000386	CcSEcCtD
Tiagabine—Vomiting—Etoposide—urinary bladder cancer	0.000291	0.000385	CcSEcCtD
Tiagabine—Anaemia—Epirubicin—urinary bladder cancer	0.00029	0.000385	CcSEcCtD
Tiagabine—Agitation—Epirubicin—urinary bladder cancer	0.000289	0.000383	CcSEcCtD
Tiagabine—Rash—Etoposide—urinary bladder cancer	0.000288	0.000382	CcSEcCtD
Tiagabine—Dermatitis—Etoposide—urinary bladder cancer	0.000288	0.000382	CcSEcCtD
Tiagabine—Headache—Etoposide—urinary bladder cancer	0.000287	0.00038	CcSEcCtD
Tiagabine—Flatulence—Doxorubicin—urinary bladder cancer	0.000286	0.00038	CcSEcCtD
Tiagabine—Chest pain—Methotrexate—urinary bladder cancer	0.000286	0.000379	CcSEcCtD
Tiagabine—Arthralgia—Methotrexate—urinary bladder cancer	0.000286	0.000379	CcSEcCtD
Tiagabine—Myalgia—Methotrexate—urinary bladder cancer	0.000286	0.000379	CcSEcCtD
Tiagabine—Tension—Doxorubicin—urinary bladder cancer	0.000285	0.000378	CcSEcCtD
Tiagabine—Dysgeusia—Doxorubicin—urinary bladder cancer	0.000285	0.000377	CcSEcCtD
Tiagabine—Malaise—Epirubicin—urinary bladder cancer	0.000283	0.000375	CcSEcCtD
Tiagabine—Discomfort—Methotrexate—urinary bladder cancer	0.000282	0.000374	CcSEcCtD
Tiagabine—Nervousness—Doxorubicin—urinary bladder cancer	0.000282	0.000374	CcSEcCtD
Tiagabine—Vertigo—Epirubicin—urinary bladder cancer	0.000282	0.000374	CcSEcCtD
Tiagabine—Syncope—Epirubicin—urinary bladder cancer	0.000282	0.000373	CcSEcCtD
Tiagabine—Leukopenia—Epirubicin—urinary bladder cancer	0.000281	0.000373	CcSEcCtD
Tiagabine—Back pain—Doxorubicin—urinary bladder cancer	0.000281	0.000373	CcSEcCtD
Tiagabine—Muscle spasms—Doxorubicin—urinary bladder cancer	0.000279	0.00037	CcSEcCtD
Tiagabine—Palpitations—Epirubicin—urinary bladder cancer	0.000278	0.000368	CcSEcCtD
Tiagabine—Confusional state—Methotrexate—urinary bladder cancer	0.000276	0.000366	CcSEcCtD
Tiagabine—Loss of consciousness—Epirubicin—urinary bladder cancer	0.000276	0.000366	CcSEcCtD
Tiagabine—Cough—Epirubicin—urinary bladder cancer	0.000274	0.000363	CcSEcCtD
Tiagabine—Infection—Methotrexate—urinary bladder cancer	0.000272	0.000361	CcSEcCtD
Tiagabine—Nausea—Etoposide—urinary bladder cancer	0.000272	0.00036	CcSEcCtD
Tiagabine—Hypertension—Epirubicin—urinary bladder cancer	0.000271	0.000359	CcSEcCtD
Tiagabine—Ill-defined disorder—Doxorubicin—urinary bladder cancer	0.00027	0.000357	CcSEcCtD
Tiagabine—Anaemia—Doxorubicin—urinary bladder cancer	0.000269	0.000356	CcSEcCtD
Tiagabine—Thrombocytopenia—Methotrexate—urinary bladder cancer	0.000268	0.000355	CcSEcCtD
Tiagabine—Myalgia—Epirubicin—urinary bladder cancer	0.000267	0.000354	CcSEcCtD
Tiagabine—Arthralgia—Epirubicin—urinary bladder cancer	0.000267	0.000354	CcSEcCtD
Tiagabine—Chest pain—Epirubicin—urinary bladder cancer	0.000267	0.000354	CcSEcCtD
Tiagabine—Agitation—Doxorubicin—urinary bladder cancer	0.000267	0.000354	CcSEcCtD
Tiagabine—Anxiety—Epirubicin—urinary bladder cancer	0.000267	0.000353	CcSEcCtD
Tiagabine—Hyperhidrosis—Methotrexate—urinary bladder cancer	0.000265	0.000351	CcSEcCtD
Tiagabine—Discomfort—Epirubicin—urinary bladder cancer	0.000264	0.00035	CcSEcCtD
Tiagabine—Malaise—Doxorubicin—urinary bladder cancer	0.000262	0.000347	CcSEcCtD
Tiagabine—Dry mouth—Epirubicin—urinary bladder cancer	0.000262	0.000347	CcSEcCtD
Tiagabine—Vertigo—Doxorubicin—urinary bladder cancer	0.000261	0.000346	CcSEcCtD
Tiagabine—Anorexia—Methotrexate—urinary bladder cancer	0.000261	0.000346	CcSEcCtD
Tiagabine—Syncope—Doxorubicin—urinary bladder cancer	0.000261	0.000345	CcSEcCtD
Tiagabine—Leukopenia—Doxorubicin—urinary bladder cancer	0.00026	0.000345	CcSEcCtD
Tiagabine—Confusional state—Epirubicin—urinary bladder cancer	0.000259	0.000343	CcSEcCtD
Tiagabine—Palpitations—Doxorubicin—urinary bladder cancer	0.000257	0.00034	CcSEcCtD
Tiagabine—Oedema—Epirubicin—urinary bladder cancer	0.000256	0.00034	CcSEcCtD
Tiagabine—Hypotension—Methotrexate—urinary bladder cancer	0.000256	0.000339	CcSEcCtD
Tiagabine—CYP3A4—Biological oxidations—NAT2—urinary bladder cancer	0.000256	0.0031	CbGpPWpGaD
Tiagabine—Loss of consciousness—Doxorubicin—urinary bladder cancer	0.000256	0.000339	CcSEcCtD
Tiagabine—Infection—Epirubicin—urinary bladder cancer	0.000255	0.000338	CcSEcCtD
Tiagabine—Cough—Doxorubicin—urinary bladder cancer	0.000254	0.000336	CcSEcCtD
Tiagabine—CYP3A4—Metapathway biotransformation—NAT2—urinary bladder cancer	0.000252	0.00306	CbGpPWpGaD
Tiagabine—Shock—Epirubicin—urinary bladder cancer	0.000252	0.000334	CcSEcCtD
Tiagabine—Thrombocytopenia—Epirubicin—urinary bladder cancer	0.000251	0.000333	CcSEcCtD
Tiagabine—Hypertension—Doxorubicin—urinary bladder cancer	0.000251	0.000333	CcSEcCtD
Tiagabine—Tachycardia—Epirubicin—urinary bladder cancer	0.00025	0.000332	CcSEcCtD
Tiagabine—Musculoskeletal discomfort—Methotrexate—urinary bladder cancer	0.00025	0.000331	CcSEcCtD
Tiagabine—Hyperhidrosis—Epirubicin—urinary bladder cancer	0.000248	0.000328	CcSEcCtD
Tiagabine—Insomnia—Methotrexate—urinary bladder cancer	0.000248	0.000328	CcSEcCtD
Tiagabine—Myalgia—Doxorubicin—urinary bladder cancer	0.000247	0.000328	CcSEcCtD
Tiagabine—Chest pain—Doxorubicin—urinary bladder cancer	0.000247	0.000328	CcSEcCtD
Tiagabine—Arthralgia—Doxorubicin—urinary bladder cancer	0.000247	0.000328	CcSEcCtD
Tiagabine—Anxiety—Doxorubicin—urinary bladder cancer	0.000247	0.000327	CcSEcCtD
Tiagabine—Paraesthesia—Methotrexate—urinary bladder cancer	0.000246	0.000326	CcSEcCtD
Tiagabine—Discomfort—Doxorubicin—urinary bladder cancer	0.000245	0.000324	CcSEcCtD
Tiagabine—Anorexia—Epirubicin—urinary bladder cancer	0.000244	0.000324	CcSEcCtD
Tiagabine—Dyspnoea—Methotrexate—urinary bladder cancer	0.000244	0.000324	CcSEcCtD
Tiagabine—Somnolence—Methotrexate—urinary bladder cancer	0.000244	0.000323	CcSEcCtD
Tiagabine—Dry mouth—Doxorubicin—urinary bladder cancer	0.000242	0.000321	CcSEcCtD
Tiagabine—Dyspepsia—Methotrexate—urinary bladder cancer	0.000241	0.00032	CcSEcCtD
Tiagabine—Hypotension—Epirubicin—urinary bladder cancer	0.00024	0.000317	CcSEcCtD
Tiagabine—Confusional state—Doxorubicin—urinary bladder cancer	0.000239	0.000317	CcSEcCtD
Tiagabine—Decreased appetite—Methotrexate—urinary bladder cancer	0.000238	0.000316	CcSEcCtD
Tiagabine—Oedema—Doxorubicin—urinary bladder cancer	0.000237	0.000314	CcSEcCtD
Tiagabine—Fatigue—Methotrexate—urinary bladder cancer	0.000236	0.000313	CcSEcCtD
Tiagabine—Infection—Doxorubicin—urinary bladder cancer	0.000236	0.000312	CcSEcCtD
Tiagabine—Pain—Methotrexate—urinary bladder cancer	0.000234	0.00031	CcSEcCtD
Tiagabine—Musculoskeletal discomfort—Epirubicin—urinary bladder cancer	0.000234	0.00031	CcSEcCtD
Tiagabine—Shock—Doxorubicin—urinary bladder cancer	0.000233	0.000309	CcSEcCtD
Tiagabine—Thrombocytopenia—Doxorubicin—urinary bladder cancer	0.000232	0.000308	CcSEcCtD
Tiagabine—Insomnia—Epirubicin—urinary bladder cancer	0.000232	0.000307	CcSEcCtD
Tiagabine—Tachycardia—Doxorubicin—urinary bladder cancer	0.000232	0.000307	CcSEcCtD
Tiagabine—Paraesthesia—Epirubicin—urinary bladder cancer	0.00023	0.000305	CcSEcCtD
Tiagabine—Hyperhidrosis—Doxorubicin—urinary bladder cancer	0.000229	0.000304	CcSEcCtD
Tiagabine—Dyspnoea—Epirubicin—urinary bladder cancer	0.000229	0.000303	CcSEcCtD
Tiagabine—Somnolence—Epirubicin—urinary bladder cancer	0.000228	0.000302	CcSEcCtD
Tiagabine—Anorexia—Doxorubicin—urinary bladder cancer	0.000226	0.0003	CcSEcCtD
Tiagabine—Feeling abnormal—Methotrexate—urinary bladder cancer	0.000226	0.000299	CcSEcCtD
Tiagabine—Dyspepsia—Epirubicin—urinary bladder cancer	0.000226	0.000299	CcSEcCtD
Tiagabine—Gastrointestinal pain—Methotrexate—urinary bladder cancer	0.000224	0.000297	CcSEcCtD
Tiagabine—Decreased appetite—Epirubicin—urinary bladder cancer	0.000223	0.000295	CcSEcCtD
Tiagabine—Hypotension—Doxorubicin—urinary bladder cancer	0.000222	0.000294	CcSEcCtD
Tiagabine—Fatigue—Epirubicin—urinary bladder cancer	0.000221	0.000293	CcSEcCtD
Tiagabine—Pain—Epirubicin—urinary bladder cancer	0.000219	0.000291	CcSEcCtD
Tiagabine—Constipation—Epirubicin—urinary bladder cancer	0.000219	0.000291	CcSEcCtD
Tiagabine—Urticaria—Methotrexate—urinary bladder cancer	0.000218	0.000288	CcSEcCtD
Tiagabine—Body temperature increased—Methotrexate—urinary bladder cancer	0.000217	0.000287	CcSEcCtD
Tiagabine—Abdominal pain—Methotrexate—urinary bladder cancer	0.000217	0.000287	CcSEcCtD
Tiagabine—Musculoskeletal discomfort—Doxorubicin—urinary bladder cancer	0.000216	0.000286	CcSEcCtD
Tiagabine—Insomnia—Doxorubicin—urinary bladder cancer	0.000215	0.000284	CcSEcCtD
Tiagabine—Paraesthesia—Doxorubicin—urinary bladder cancer	0.000213	0.000282	CcSEcCtD
Tiagabine—Dyspnoea—Doxorubicin—urinary bladder cancer	0.000212	0.00028	CcSEcCtD
Tiagabine—Feeling abnormal—Epirubicin—urinary bladder cancer	0.000211	0.00028	CcSEcCtD
Tiagabine—Somnolence—Doxorubicin—urinary bladder cancer	0.000211	0.000279	CcSEcCtD
Tiagabine—Gastrointestinal pain—Epirubicin—urinary bladder cancer	0.00021	0.000278	CcSEcCtD
Tiagabine—Dyspepsia—Doxorubicin—urinary bladder cancer	0.000209	0.000277	CcSEcCtD
Tiagabine—Decreased appetite—Doxorubicin—urinary bladder cancer	0.000206	0.000273	CcSEcCtD
Tiagabine—Fatigue—Doxorubicin—urinary bladder cancer	0.000205	0.000271	CcSEcCtD
Tiagabine—CYP3A4—Biological oxidations—HPGDS—urinary bladder cancer	0.000204	0.00248	CbGpPWpGaD
Tiagabine—Urticaria—Epirubicin—urinary bladder cancer	0.000204	0.00027	CcSEcCtD
Tiagabine—Constipation—Doxorubicin—urinary bladder cancer	0.000203	0.000269	CcSEcCtD
Tiagabine—Pain—Doxorubicin—urinary bladder cancer	0.000203	0.000269	CcSEcCtD
Tiagabine—Body temperature increased—Epirubicin—urinary bladder cancer	0.000203	0.000269	CcSEcCtD
Tiagabine—Abdominal pain—Epirubicin—urinary bladder cancer	0.000203	0.000269	CcSEcCtD
Tiagabine—Hypersensitivity—Methotrexate—urinary bladder cancer	0.000202	0.000267	CcSEcCtD
Tiagabine—CYP3A4—Biological oxidations—GSTT1—urinary bladder cancer	0.000198	0.00241	CbGpPWpGaD
Tiagabine—Asthenia—Methotrexate—urinary bladder cancer	0.000197	0.00026	CcSEcCtD
Tiagabine—Feeling abnormal—Doxorubicin—urinary bladder cancer	0.000196	0.000259	CcSEcCtD
Tiagabine—Gastrointestinal pain—Doxorubicin—urinary bladder cancer	0.000194	0.000257	CcSEcCtD
Tiagabine—Pruritus—Methotrexate—urinary bladder cancer	0.000194	0.000257	CcSEcCtD
Tiagabine—Hypersensitivity—Epirubicin—urinary bladder cancer	0.000189	0.00025	CcSEcCtD
Tiagabine—Urticaria—Doxorubicin—urinary bladder cancer	0.000188	0.00025	CcSEcCtD
Tiagabine—Abdominal pain—Doxorubicin—urinary bladder cancer	0.000188	0.000248	CcSEcCtD
Tiagabine—Body temperature increased—Doxorubicin—urinary bladder cancer	0.000188	0.000248	CcSEcCtD
Tiagabine—Diarrhoea—Methotrexate—urinary bladder cancer	0.000187	0.000248	CcSEcCtD
Tiagabine—Asthenia—Epirubicin—urinary bladder cancer	0.000184	0.000244	CcSEcCtD
Tiagabine—Pruritus—Epirubicin—urinary bladder cancer	0.000181	0.00024	CcSEcCtD
Tiagabine—Dizziness—Methotrexate—urinary bladder cancer	0.000181	0.00024	CcSEcCtD
Tiagabine—Diarrhoea—Epirubicin—urinary bladder cancer	0.000175	0.000232	CcSEcCtD
Tiagabine—Hypersensitivity—Doxorubicin—urinary bladder cancer	0.000175	0.000232	CcSEcCtD
Tiagabine—Vomiting—Methotrexate—urinary bladder cancer	0.000174	0.000231	CcSEcCtD
Tiagabine—Rash—Methotrexate—urinary bladder cancer	0.000173	0.000229	CcSEcCtD
Tiagabine—Dermatitis—Methotrexate—urinary bladder cancer	0.000173	0.000229	CcSEcCtD
Tiagabine—Headache—Methotrexate—urinary bladder cancer	0.000172	0.000227	CcSEcCtD
Tiagabine—Asthenia—Doxorubicin—urinary bladder cancer	0.00017	0.000226	CcSEcCtD
Tiagabine—Dizziness—Epirubicin—urinary bladder cancer	0.00017	0.000225	CcSEcCtD
Tiagabine—Pruritus—Doxorubicin—urinary bladder cancer	0.000168	0.000222	CcSEcCtD
Tiagabine—Vomiting—Epirubicin—urinary bladder cancer	0.000163	0.000216	CcSEcCtD
Tiagabine—Nausea—Methotrexate—urinary bladder cancer	0.000163	0.000216	CcSEcCtD
Tiagabine—Diarrhoea—Doxorubicin—urinary bladder cancer	0.000162	0.000215	CcSEcCtD
Tiagabine—Rash—Epirubicin—urinary bladder cancer	0.000162	0.000214	CcSEcCtD
Tiagabine—Dermatitis—Epirubicin—urinary bladder cancer	0.000162	0.000214	CcSEcCtD
Tiagabine—Headache—Epirubicin—urinary bladder cancer	0.000161	0.000213	CcSEcCtD
Tiagabine—Dizziness—Doxorubicin—urinary bladder cancer	0.000157	0.000208	CcSEcCtD
Tiagabine—Nausea—Epirubicin—urinary bladder cancer	0.000152	0.000202	CcSEcCtD
Tiagabine—Vomiting—Doxorubicin—urinary bladder cancer	0.000151	0.0002	CcSEcCtD
Tiagabine—Rash—Doxorubicin—urinary bladder cancer	0.00015	0.000198	CcSEcCtD
Tiagabine—Dermatitis—Doxorubicin—urinary bladder cancer	0.000149	0.000198	CcSEcCtD
Tiagabine—Headache—Doxorubicin—urinary bladder cancer	0.000149	0.000197	CcSEcCtD
Tiagabine—Nausea—Doxorubicin—urinary bladder cancer	0.000141	0.000187	CcSEcCtD
Tiagabine—CYP3A4—Biological oxidations—GSTP1—urinary bladder cancer	0.000137	0.00167	CbGpPWpGaD
Tiagabine—CYP3A4—Metapathway biotransformation—GSTP1—urinary bladder cancer	0.000136	0.00164	CbGpPWpGaD
Tiagabine—CYP3A4—Biological oxidations—GSTM1—urinary bladder cancer	0.000126	0.00153	CbGpPWpGaD
Tiagabine—CYP3A4—Metapathway biotransformation—GSTM1—urinary bladder cancer	0.000125	0.00151	CbGpPWpGaD
Tiagabine—CYP3A4—Metabolism—GSTZ1—urinary bladder cancer	8.42e-05	0.00102	CbGpPWpGaD
Tiagabine—CYP3A4—Metabolism—GSTO2—urinary bladder cancer	7.98e-05	0.000968	CbGpPWpGaD
Tiagabine—CYP3A4—Metabolism—NAT1—urinary bladder cancer	7.98e-05	0.000968	CbGpPWpGaD
Tiagabine—CYP3A4—Metabolism—UGT2B7—urinary bladder cancer	7.3e-05	0.000886	CbGpPWpGaD
Tiagabine—CYP3A4—Metabolism—CYP4B1—urinary bladder cancer	6.57e-05	0.000798	CbGpPWpGaD
Tiagabine—CYP3A4—Metabolism—SLC19A1—urinary bladder cancer	6.21e-05	0.000753	CbGpPWpGaD
Tiagabine—CYP3A4—Metabolism—PRSS3—urinary bladder cancer	6.05e-05	0.000734	CbGpPWpGaD
Tiagabine—CYP3A4—Metabolism—TYMP—urinary bladder cancer	4.84e-05	0.000587	CbGpPWpGaD
Tiagabine—CYP3A4—Metabolism—NAT2—urinary bladder cancer	4.37e-05	0.000531	CbGpPWpGaD
Tiagabine—CYP3A4—Metabolism—RRM2—urinary bladder cancer	3.78e-05	0.000458	CbGpPWpGaD
Tiagabine—CYP3A4—Metabolism—HPGDS—urinary bladder cancer	3.5e-05	0.000424	CbGpPWpGaD
Tiagabine—CYP3A4—Metabolism—ENO2—urinary bladder cancer	3.5e-05	0.000424	CbGpPWpGaD
Tiagabine—CYP3A4—Metabolism—GSTT1—urinary bladder cancer	3.39e-05	0.000411	CbGpPWpGaD
Tiagabine—CYP3A4—Metabolism—NQO1—urinary bladder cancer	2.82e-05	0.000342	CbGpPWpGaD
Tiagabine—CYP3A4—Metabolism—GSTP1—urinary bladder cancer	2.35e-05	0.000285	CbGpPWpGaD
Tiagabine—CYP3A4—Metabolism—TYMS—urinary bladder cancer	2.19e-05	0.000265	CbGpPWpGaD
Tiagabine—CYP3A4—Metabolism—GSTM1—urinary bladder cancer	2.16e-05	0.000262	CbGpPWpGaD
Tiagabine—CYP3A4—Metabolism—NCOR1—urinary bladder cancer	2.16e-05	0.000262	CbGpPWpGaD
Tiagabine—CYP3A4—Metabolism—GPX1—urinary bladder cancer	2.07e-05	0.000251	CbGpPWpGaD
Tiagabine—CYP3A4—Metabolism—ERCC2—urinary bladder cancer	2.03e-05	0.000246	CbGpPWpGaD
Tiagabine—CYP3A4—Metabolism—MTHFR—urinary bladder cancer	1.91e-05	0.000232	CbGpPWpGaD
Tiagabine—CYP3A4—Metabolism—PPARG—urinary bladder cancer	1.55e-05	0.000188	CbGpPWpGaD
Tiagabine—CYP3A4—Metabolism—CREBBP—urinary bladder cancer	1.49e-05	0.00018	CbGpPWpGaD
Tiagabine—CYP3A4—Metabolism—PTGS2—urinary bladder cancer	1.22e-05	0.000148	CbGpPWpGaD
Tiagabine—CYP3A4—Metabolism—PTEN—urinary bladder cancer	1.06e-05	0.000129	CbGpPWpGaD
Tiagabine—CYP3A4—Metabolism—EP300—urinary bladder cancer	1.01e-05	0.000123	CbGpPWpGaD
